Found: 10
Select item for more details and to access through your institution.
The Efficacy and Safety of Tadalafil 5 mg Once Daily in Korean Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: An Integrated Analysis.
- Published in:
- World Journal of Men's Health, 2014, v. 32, n. 1, p. 28, doi. 10.5534/wjmh.2014.32.1.28
- By:
- Publication type:
- Article
Ixekizumab 80 mg Every 2 Weeks Treatment Beyond Week 12 for Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 2, p. 481, doi. 10.1007/s13555-021-00666-x
- By:
- Publication type:
- Article
Japanese growth prediction model for prepubertal children with growth hormone deficiency.
- Published in:
- Journal of Pediatric Endocrinology & Metabolism, 2012, v. 25, n. 9/10, p. 909, doi. 10.1515/jpem-2012-0189
- By:
- Publication type:
- Article
Tadalafil 5 mg once daily for the treatment of Asian men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: Analyses of data pooled from three randomized, double-blind, placebo-controlled studies.
- Published in:
- International Journal of Urology, 2015, v. 22, n. 4, p. 378, doi. 10.1111/iju.12699
- By:
- Publication type:
- Article
Tadalafil 5 mg once-daily therapy for men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: Results from a randomized, double-blind, placebo-controlled trial carried out in Japan and Korea.
- Published in:
- International Journal of Urology, 2014, v. 21, n. 7, p. 670, doi. 10.1111/iju.12410
- By:
- Publication type:
- Article
Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A randomized placebo- and tamsulosin-controlled 12-week study in Asian men.
- Published in:
- International Journal of Urology, 2013, v. 20, n. 2, p. 193, doi. 10.1111/j.1442-2042.2012.03130.x
- By:
- Publication type:
- Article
Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study ( UNCOVER-J).
- Published in:
- Journal of Dermatology, 2017, v. 44, n. 4, p. 355, doi. 10.1111/1346-8138.13622
- By:
- Publication type:
- Article
Correction: Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1).
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1).
- Published in:
- Rheumatology & Therapy, 2023, v. 10, n. 6, p. 1683, doi. 10.1007/s40744-023-00605-6
- By:
- Publication type:
- Article
Tadalafil for the Treatment of Lower Urinary Tract Symptoms in Japanese Men with Benign Prostatic Hyperplasia: Results from a 12-week Placebo-controlled Dose-finding Study with a 42-week Open-label Extension.
- Published in:
- LUTS, 2012, v. 4, n. 3, p. 110, doi. 10.1111/j.1757-5672.2012.00144.x
- By:
- Publication type:
- Article